Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

13 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Upfront lower dose lenalidomide is less toxic and does not compromise efficacy for vulnerable patients with relapsed refractory multiple myeloma: final analysis of the phase II RevLite study.
Quach H, Fernyhough L, Henderson R, Corbett G, Baker B, Browett P, Blacklock H, Forsyth C, Underhill C, Cannell P, Trotman J, Neylon A, Harrison S, Link E, Swern A, Cowan L, Dimopoulos MA, Miles Prince H. Quach H, et al. Among authors: miles prince h. Br J Haematol. 2017 May;177(3):441-448. doi: 10.1111/bjh.14562. Epub 2017 Feb 15. Br J Haematol. 2017. PMID: 28197996 Free article. Clinical Trial.
The influence of unmet supportive care needs on anxiety and depression during cancer treatment and beyond: a longitudinal study of survivors of haematological cancers.
Oberoi D, White VM, Seymour JF, Miles Prince H, Harrison S, Jefford M, Winship I, Hill D, Bolton D, Kay A, Millar J, Doo NW, Giles G. Oberoi D, et al. Among authors: miles prince h. Support Care Cancer. 2017 Nov;25(11):3447-3456. doi: 10.1007/s00520-017-3766-9. Epub 2017 Jun 30. Support Care Cancer. 2017. PMID: 28667564
Considerations for pre-transfusion immunohaematology testing in patients receiving the anti-CD38 monoclonal antibody daratumumab for the treatment of multiple myeloma.
Quach H, Benson S, Haysom H, Wilkes AM, Zacher N, Cole-Sinclair M, Miles Prince H, Mollee P, Spencer A, Joy Ho P, Harrison SJ, Lee C, Augustson B, Daly J. Quach H, et al. Among authors: miles prince h. Intern Med J. 2018 Feb;48(2):210-220. doi: 10.1111/imj.13707. Intern Med J. 2018. PMID: 29415351 Review.
Isatuximab plus pomalidomide and dexamethasone in relapsed/refractory multiple myeloma patients with renal impairment: ICARIA-MM subgroup analysis.
Dimopoulos MA, Leleu X, Moreau P, Richardson PG, Liberati AM, Harrison SJ, Miles Prince H, Ocio EM, Assadourian S, Campana F, Malinge L, Sémiond D, van de Velde H, Yong K. Dimopoulos MA, et al. Among authors: miles prince h. Leukemia. 2021 Feb;35(2):562-572. doi: 10.1038/s41375-020-0868-z. Epub 2020 May 23. Leukemia. 2021. PMID: 32444867 Free PMC article. Clinical Trial.
Daratumumab, lenalidomide, and dexamethasone in relapsed/refractory myeloma: a cytogenetic subgroup analysis of POLLUX.
Kaufman JL, Dimopoulos MA, White D, Benboubker L, Cook G, Leiba M, Morton J, Joy Ho P, Kim K, Takezako N, Moreau P, Sutherland HJ, Magen H, Iida S, Kim JS, Miles Prince H, Cochrane T, Oriol A, Bahlis NJ, Chari A, O'Rourke L, Trivedi S, Casneuf T, Krevvata M, Ukropec J, Kobos R, Avet-Loiseau H, Usmani SZ, San-Miguel J. Kaufman JL, et al. Among authors: miles prince h. Blood Cancer J. 2020 Nov 3;10(11):111. doi: 10.1038/s41408-020-00375-2. Blood Cancer J. 2020. PMID: 33149130 Free PMC article. Clinical Trial.
Elranatamab in relapsed or refractory multiple myeloma: phase 2 MagnetisMM-3 trial results.
Lesokhin AM, Tomasson MH, Arnulf B, Bahlis NJ, Miles Prince H, Niesvizky R, Rodrίguez-Otero P, Martinez-Lopez J, Koehne G, Touzeau C, Jethava Y, Quach H, Depaus J, Yokoyama H, Gabayan AE, Stevens DA, Nooka AK, Manier S, Raje N, Iida S, Raab MS, Searle E, Leip E, Sullivan ST, Conte U, Elmeliegy M, Czibere A, Viqueira A, Mohty M. Lesokhin AM, et al. Among authors: miles prince h. Nat Med. 2023 Sep;29(9):2259-2267. doi: 10.1038/s41591-023-02528-9. Epub 2023 Aug 15. Nat Med. 2023. PMID: 37582952 Free PMC article. Clinical Trial.
Erratum to: Romidepsin for the treatment of relapsed/refractory peripheral T cell lymphoma: prolonged stable disease provides clinical benefits for patients in the pivotal trial.
Foss F, Horwitz S, Pro B, Miles Prince H, Sokol L, Balser B, Wolfson J, Coiffier B. Foss F, et al. Among authors: miles prince h. J Hematol Oncol. 2017 Sep 18;10(1):154. doi: 10.1186/s13045-017-0518-8. J Hematol Oncol. 2017. PMID: 28923081 Free PMC article. No abstract available.
13 results